Purpose of Review
Pacing in pediatric and adult patients with congenital heart disease requires careful evaluation and thoughtful planning. Review of current guidelines with assessment of risk/benefit must be performed along with planning on a case-by-case basis in order to achieve maximal success and reduce risk in this specialized population of patients that is rapidly increasing in size.
Guidelines for pacing in pediatric and congenital heart disease patients span many years. Most recent consensus and summary guidelines address pacing in adult patients with or without congenital heart disease. Pediatric recommendations from prior documents must be included in current decision-making.
Pacing in pediatric and congenital heart disease patients is important therapy. Creation of an individualized plan of care with attention to risk/benefit decision-making regarding when and how to pace is critical in this population to maximize beneficial outcome.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
•• Epstein AE, JP DM, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):e1–62 This document provides the most thorough evidence-based guidelines for cardiac rhythm management devices specific to the pediatric and congenital heart disease population. An update to this article was published in 2018, but indications specific to the pediatric population were not as robust as in the original article.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61(3):e6–75.
• Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):932–87. This is an updated guideline regarding pacing in patients with bradycardia and conduction delay. However, this document does not have pediatric or congenital heart disease specific recommendations.
• Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, et al. PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). Can J Cardiol. 2014;30(10):e1–e63 This document, developed by the Pediatric and Congenital Electrophysiology Society, sets a framework for management of rhythm disturbances in adult patients with congenital heart disease.
Wilhelm BJ, Thone M, El-Scheich T, Livert D, Angelico R, Osswald B. Complications and risk assessment of 25 years in pediatric pacing. Ann Thorac Surg. 2015;100(1):147–53.
Silvetti MS, Drago F, Grutter G, De Santis A, Di Ciommo V, Rava L. Twenty years of paediatric cardiac pacing: 515 pacemakers and 480 leads implanted in 292 patients. Europace. 2006;8(7):530–6.
Lau KC, William Gaynor J, Fuller SM, Karen AS, Shah MJ. Long-term atrial and ventricular epicardial pacemaker lead survival after cardiac operations in pediatric patients with congenital heart disease. Heart Rhythm. 2015;12(3):566–73.
Silvetti MS, Drago F, Di Carlo D, Placidi S, Brancaccio G, Carotti A. Cardiac pacing in paediatric patients with congenital heart defects: transvenous or epicardial? Europace. 2013;15(9):1280–6.
Bar-Cohen Y, Berul CI, Alexander ME, Fortescue EB, Walsh EP, Triedman JK, et al. Age, size, and lead factors alone do not predict venous obstruction in children and young adults with transvenous lead systems. J Cardiovasc Electrophysiol. 2006;17(7):754–9.
Shah MJ, Nehgme R, Carboni M, Murphy JD. Endocardial atrial pacing lead implantation and midterm follow-up in young patients with sinus node dysfunction after the Fontan procedure. Pacing Clin Electrophysiol. 2004;27(7):949–54.
Takahashi K, Cecchin F, Fortescue E, Berul CI, Alexander ME, Walsh EP, et al. Permanent atrial pacing lead implant route after Fontan operation. Pacing Clin Electrophysiol. 2009;32(6):779–85.
Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm. 2014;11(9):1619–25.
Niu MC, Morris SA, Krenek M, DLU CM, Pedroza C, Miyake CY, et al. Reassessing risk factors in pediatric patients with pacemakers implanted for atrioventricular block: the impact of nonsustained ventricular tachycardia. J Cardiovasc Electrophysiol. 2016;27(4):471–9.
Moak JP, Barron KS, Hougen TJ, Wiles HB, Balaji S, Sreeram N, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol. 2001;37(1):238–42.
Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol. 2002;39(1):130–7.
Lillehei CW, Sellers RD, Bonnabeau RC, Eliot RS. Chronic postsurgical complete heart block. With particular reference to prognosis, management, and a new P-wave pacemaker. J Thorac Cardiovasc Surg. 1963;46:436–56.
Krongrad E. Prognosis for patients with congenital heart disease and postoperative intraventricular conduction defects. Circulation. 1978;57(5):867–70.
Weindling SN, Saul JP, Gamble WJ, Mayer JE, Wessel D, Walsh EP. Duration of complete atrioventricular block after congenital heart disease surgery. Am J Cardiol. 1998;82(4):525–7.
Murray LE, Smith AH, Flack EC, Crum K, Owen J, Kannankeril PJ. Genotypic and phenotypic predictors of complete heart block and recovery of conduction after surgical repair of congenital heart disease. Heart Rhythm. 2017;14(3):402–9.
Gross GJ, Chiu CC, Hamilton RM, Kirsh JA, Stephenson EA. Natural history of postoperative heart block in congenital heart disease: implications for pacing intervention. Heart Rhythm. 2006;3(5):601–4.
Villain E, Ouarda F, Beyler C, Sidi D, Abid F. Predictive factors for late complete atrioventricular block after surgical treatment for congenital cardiopathy. Arch Mal Coeur Vaiss. 2003;96(5):495–8.
Baruteau AE, Abrams DJ, Ho SY, Thambo JB, McLeod CJ, Shah MJ. Cardiac conduction system in congenitally corrected transposition of the great arteries and its clinical relevance. J Am Heart Assoc. 2017;6(12). https://www.ahajournals.org/doi/full/10.1161/JAHA.117.007759.
Cohen MI, Rhodes LA, Spray TL, Gaynor JW. Efficacy of prophylactic epicardial pacing leads in children and young adults. Ann Thorac Surg. 2004;78(1):197–202 discussion −3.
Sasaki J, Lopez MM, Baysa SJ, Kanter RJ, Rossi AF. Utility of preoperative Holter monitoring in children undergoing extracardiac conduit Fontan operation. Pacing Clin Electrophysiol. 2017;40(12):1472–8.
Garson A Jr, Bink-Boelkens M, Hesslein PS, Hordof AJ, Keane JF, Neches WH, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol. 1985;6(4):871–8.
Rhodes LA, Walsh EP, Gamble WJ, Triedman JK, Saul JP. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol. 1995;18(5 Pt 1):1005–16.
Opic P, Yap SC, Van Kranenburg M, Van Dijk AP, Budts W, Vliegen HW, et al. Atrial-based pacing has no benefit over ventricular pacing in preventing atrial arrhythmias in adults with congenital heart disease. Europace. 2013;15(12):1757–62.
Kamp AN, LaPage MJ, Serwer GA, Dick M 2nd, Bradley DJ. Antitachycardia pacemakers in congenital heart disease. Congenit Heart Dis. 2015;10(2):180–4.
Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, et al. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol. 2005;46(12):2277–83.
Conflict of Interest
M. David Weiland and Salim F. Idriss declare that they have no conflict of interest.
Zebulon Spector reports personal fees from Janssen Research & Development.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Congenital Heart Disease.
About this article
Cite this article
Weiland, M.D., Spector, Z. & Idriss, S.F. Pacing in Patients with Congenital Heart Disease: When Is It Helpful and When Is It Harmful?. Curr Cardiol Rep 22, 5 (2020) doi:10.1007/s11886-020-1253-2
- Congenital heart disease
- Complete heart block